Malignant neoplasm of breast
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our in vivo experiments also show that GL-V9 significantly inhibits the growth of human breast cancer due to activation of GSK-3β and inactivation of AKT.
|
31669347 |
2020 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings reveal that downregulation of miR-1469 may promote the development of BC by targeting HOXA1 and activating PTEN/PI3K/AKT and Wnt/β-catenin pathways.
|
30320894 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Capivasertib 480 mg bid rapidly modulates key biomarkers of the AKT pathway and decreases proliferation marker Ki67, suggesting future potential as an effective therapy in AKT-dependent breast cancers.
|
31836609 |
2019 |
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
|
31698236 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, this review aimed to give a comprehensive overview about the isoform-specific effects of AKT in breast cancer and to summarize known downstream and upstream mechanisms.
|
31752925 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
The results of our study provide new insights into an oncogenic role of PLAC8 and reveal a novel PLAC8/ PI3K/AKT/NF-κB pathway as a potential therapeutic target for BC.
|
31448883 |
2019 |
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the PI3K/AKT pathway are frequently found in cancer and are especially common in breast cancer, where it is estimated that 70% of tumors have some type of genetic alteration that could lead to pathway hyperactivation.
|
31626273 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1α) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells.
|
30930461 |
2019 |
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
|
29540052 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
RHAMM inhibits cell migration via the AKT/GSK3β/Snail axis in luminal A subtype breast cancer.
|
31769593 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our study pinpoints key role of mTORC2-Akt1 axis in OSM induced macrophage polarization and suggests for possible usage of Oncostatin-M blockade and/or selective mTORC2 inhibition as a potential anti-cancer strategy particularly with reference to metastasis of breast cancer to distant organs such as lung, liver and bone.
|
29625858 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study demonstrates AKT-mediated sugar addiction in breast cancer chemoprevention by BITC.
|
30720225 |
2019 |
Malignant neoplasm of breast
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In addition, proteins expression of the PI3K-AKT-mTOR signaling pathway involved in the regulation of breast cancer were detected by Western Blotting.
|
31007610 |
2019 |
Malignant neoplasm of breast
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In this study, we experimentally manipulated <i>UEV1</i> expression in two typical breast cancer cell lines MDA-MB-231 and MCF7 under serum starvation conditions and monitored AKT activation and its downstream protein levels, as well as cellular sensitivity to chemotherapeutic agents.
|
31827405 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
We investigated the role of phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5Kα), a key upstream factor of PI3K/AKT, and the therapeutic effect of PIP5Kα inhibitor on subtypes of BC.
|
30104711 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> We have demonstrated that Linc00460 promotes breast cancer progression partly through the miR-489-5p/FGF7/AKT axis.
|
31308741 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells.
|
31771180 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Disturbing the TRIB3-AKT interaction suppresses BCSCs by accelerating FOXO1 degradation and reducing SOX2 expression in mouse models of breast cancer.
|
31844113 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
In summary, the present study indicated that the knockdown of lncRNA-HOTAIR weakened the resistance of breast cancer cells to DOX via PI3K/AKT/mTOR signaling, suggesting that lncRNA-HOTAIR may be a novel intervention target to reverse DOX-resistance in breast cancer.
|
31281438 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
First, a simplified mass spectrometric approach that maps an epitope from a digested antigen solution without immobilizing the anti-antigen antibody on a solid support will be reported. iMALDI (from immunoaffinity and MALDI, matrix-assisted laser desorption/ionization), a technique that involves immunoaffinity capture of specific peptides and direct MALDI measurements was used for absolute quantification of serine/threonine-specific protein kinase (AKT) peptides from breast cancer and colon cancer cell lines and flash-frozen tumor lysates.
|
31347059 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, the present review attempts to address the implication of key enzymes of the aerobic glycolytic pathway including hexokinase (HK), phosphofructokinase (PFK) and pyruvate kinase (PK), glucose transporters (GLUTs), together with related signaling pathways including protein kinase B(PI3K/AKT), mammalian target of rapamycin (mTOR) and adenosine monophosphate-activated protein kinase (AMPK) and transcription factors (c-myc, p53 and HIF-1) in the research of BC.
|
31359335 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight Junctions Controls Epithelial-Mesenchymal Plasticity in Breast Cancer.
|
30385615 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this review, we will discuss the rationale for targeting PI3K/AKT signaling and the development of PI3K/AKT inhibitors in breast cancer.
|
31828441 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
The data suggested that GNAS promoted breast cancer cell proliferation and migration (EMT) through the PI3K/AKT/Snail1/E-cadherin signaling pathway.
|
30767161 |
2019 |
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.
|
31781306 |
2019 |